ARCHIVES

Cancer Research Faces A “Strategic Inflection,” NCI Director Says

This article is from The Cancer Letter archive.

Vol. 28 No. 16 | April 19, 2002

Download PDF Visit The Full Archive

Related Articles

Guest Editorial By Gregory Reaman: Memories Of A Merger Past

July 15, 2011

Grants Funding: R01 Payline To tighten To 22nd Percentile This Year, NCI Says.

November 29, 1996

In Brief: No More Shifts Planned For Treatment Programs; Groups Seek Surgeon, Radiologist Incentives

August 29, 1975

New Understanding of drug Resistance Exciting Revolution

September 17, 1982

Clinical Trials Approved by NCI CTEP Last Month

August 26, 2011

ODAC Recommends Fludarabine Approval for Refractory CLL

September 21, 1990